Sugi Predict

Sugi Predict / Compounds / SCHEMBL4466121

SCHEMBL4466121

SCHEMBL4466121

Nc1nc(Nc2ccccc2F)sc1C(=O)c1ccc(OC(F)F)cc1

nearest known ligand 0.80

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.80
▸ KMT2A Q03164 5/20 0.80
▸ NPC1 O15118 5/20 0.80
▸ RAB9A P51151 3/20 0.80
▸ CLK1 P49759 1/20 0.80
▸ CDK5 Q00535 10/20 0.76
▸ CDK5R1 Q15078 10/20 0.76
▸ MAPT P10636 4/20 0.73
▸ SMN1; SMN2 Q16637 1/20 0.73
▸ LMNA P02545 2/20 0.57
▸ CCNA2 P20248 6/20 0.56
▸ CDK2 P24941 6/20 0.56
▸ GSK3A P49840 1/20 0.53
▸ GSK3B P49841 1/20 0.53
▸ MAPK14 Q16539 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ TP53 P04637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31415231 0.88 NPC1 (0.71) MEN1KMT2ANPC1RAB9ACLK1
SCHEMBL25609922 0.88 NPC1 (0.71) MEN1KMT2ANPC1RAB9ACLK1
SCHEMBL25609666 0.86 CDK5 (1.00) MEN1KMT2ANPC1RAB9ACLK1
SCHEMBL31415156 0.86 CDK5 (1.00) MEN1KMT2ANPC1RAB9ACLK1
SCHEMBL25422391 0.86 MAPT (0.65) MEN1KMT2ANPC1RAB9ACLK1
SCHEMBL25278128 0.83 MEN1 (0.80) MEN1KMT2ANPC1RAB9ACLK1
SCHEMBL31415158 0.82 MEN1 (0.62) MEN1KMT2ANPC1RAB9ACLK1
SCHEMBL25609633 0.82 MEN1 (0.62) MEN1KMT2ANPC1RAB9ACLK1
SCHEMBL4487774 0.82 CDK5 (0.68) MEN1KMT2ANPC1RAB9ACLK1
SCHEMBL4469916 0.82 MEN1 (0.56) MEN1KMT2ANPC1RAB9ACLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 — — US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 — — US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 — — US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 — — US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 — — US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 — — US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 — — US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 — — US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 — — US disclosed
US-20060041006-A1 PDE4B inhibitors and uses therefor PLEXXIKON, INC. 2006-02-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A MEN1 2737/4885KMT2A 2234/4885NPC1 2068/4885
US-20060041006-A1 PDE4B inhibitors and uses therefor PDE4B, PDE7B, PDE4A MEN1 2737/4885KMT2A 2234/4885NPC1 2068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.